THIS WEEK'S FEATURE

This Week's Feature

Gritstone bio awaits preliminary Phase 2 data for personalized neoantigen vaccine

Gritstone bio (NASDAQ: GRTS) is expecting in the first quarter of 2024 preliminary data from its Phase 2/3 study evaluating the Company's personalized neoantigen vaccine candidate for the treatment of colorectal cancer...

November 28, 2023

MORE FEATURES

Feature

Upswing Health harmonizes human touch with AI-driven technology to assess MSK pain

Closely-held Upswing Health, a virtual orthopedic company, is reinventing orthopedic care delivery through its virtual orthopedic musculoskeletal symptom assessment tool and customized pain management program...

November 21, 2023

Feature

Intrinsic Medicine developing new drugs for gut-immune-brain axis disorders

Closely-held Intrinsic medicine is developing new drugs for diseases that are linked to the disordered interaction of the gut microbiome, the immune system and the nervous system.

November 14, 2023

Feature

Rainhouse’s CNC machining expertise supporting specialty medical device manufacturing

Closely-held Rainhouse Manufacturing, a company specializing in computer numerical control (CNC) machining, quality assurance, and electronic manufacturing, is working with companies to make their medical device designs...

November 7, 2023

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

THIS WEEK'S FEATURE

Gritstone bio awaits preliminary Phase 2 data for personalized neoantigen vaccine

MORE FEATURES

Upswing Health harmonizes human touch with AI-driven technology to assess MSK pain

Intrinsic Medicine developing new drugs for gut-immune-brain axis disorders

Rainhouse’s CNC machining expertise supporting specialty medical device manufacturing

NEWS

Evercore starts Gracell Biotech at OP

Anixa reports European patent for ovarian cancer vaccine technology

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

Firefly, WaveDancer in merger agreement

LENZ Therapeutics, Graphite Bio in merger accord

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Brookline starts Annovis Bio at buy; PT $35

Just a few of the companies we’ve highlighted along the way

General

More